



ABN 53 075 582 740

ASX ANNOUNCEMENT

3 March 2016

Bionomics Limited (ASX:BNO, OTCQX: BNOEF) hereby gives notice to the Australian Securities Exchange ("ASX") that shareholders of the company did not pass the four resolutions considered before the Extraordinary General Meeting today.

The Notice of Extraordinary General Meeting and accompanying documents were lodged with ASX on 1 February 2016.

This notice is given in accordance with ASX Listing rule 3.13.2 and section 251AA of the Corporations Act 2001.

Resolution Number	Resolutions	Result	For	Against	Abstain
1	Approval for the issue of Warrants for ordinary shares – CVI Investments Inc.	The motion was Not Carried as an ordinary resolution on a Poll	105,393,796	188,451,698	2,308,340
2	Approval for the issue of Warrants for ordinary shares – Empery Group of Companies.	The motion was Not Carried as an ordinary resolution on a Poll	105,393,796	188,444,698	2,315,340
3	Approval for the issue of Warrants for ordinary shares – Sabby Group of Companies.	The motion was Not Carried as an ordinary resolution on a Poll	105,395,546	188,449,948	2,308,340
4	Approval for the issue of Warrants for ordinary shares – Biotechnology Value Fund Group of Companies.	The motion was Not Carried as an ordinary resolution on a Poll	105,386,084	188,445,660	2,322,090

FOR FURTHER INFORMATION PLEASE CONTACT:

Bionomics Limited

Dr Deborah Rathjen
 CEO & Managing Director
 +61 8 8354 6101
drathjen@bionomics.com.au

Mr Jack Moschakis
 Legal Counsel & Company Secretary
 +61 8 8354 6181
jmoschakis@bionomics.com.au

About Bionomics Limited

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates focused on the treatment of serious central nervous system disorders and on the treatment of cancer. Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of generalized anxiety disorder, is a novel, proprietary negative allosteric modulator of the alpha-7 ($\alpha 7$) nicotinic acetylcholine receptor. The Company is also developing BNC101, its lead humanized monoclonal antibody targeting a key receptor on cancer stem cells that is overexpressed in metastatic colorectal cancer, metastatic pancreatic cancer and many other solid tumours; BNC101 is expected to enter clinical trials in the fourth quarter of 2015. Bionomics has strategic partnerships with Merck & Co., Inc (known as MSD outside the United States and Canada) in pain and cognition.

www.bionomics.com.au